インスリンペン - 世界市場の考察、競合情勢、市場予測（2030年）

世界のインスリンペンの市場規模は、2024年～2030年の予測期間にCAGRで3.45％の成長が見込まれます。インスリンペンの需要の増加は主に、遺伝的要因、年齢、肥満、不健康な生活習慣による糖尿病の有病率の増加、老人患者の増加、インスリンペンを使用した自己管理の意識の向上、世界中での遠隔医療の進歩によるものであり、これらが市場を強化し、2024年～2030年の予測期間にインスリンペン市場の成長に寄与する見込みです。

インスリンペンの市場力学

インスリンペン市場は、さまざまな理由により製品需要が伸びています。遺伝、加齢、肥満、不健康な生活習慣などのさまざまな要因による世界の糖尿病の有病率の増加や、老人患者の増加、世界中のさまざまな政府の取り組みが、市場を強化すると予測されます。

世界保健機関（WHO）（2022）によると、2019年、世界中で糖尿病を直接の原因として推定150万人が死亡しており、糖尿病は第9位の死因でした。糖尿病の有病率と死亡率は、高所得国よりも低中所得国で急速に上昇しています。WHOはまた、糖尿病は失明、腎不全、心臓発作、脳卒中の主因であると結論づけています。

さらに、国際糖尿病連合（International Diabetes Federation）のDiabetes Atlas第10版（2022）によると、世界全体で5億3,700万人の成人（20～79歳）が糖尿病を患っています。この数は2030年までに6億4,300万人、2045年までに7億8,300万人に増加すると予測されています。同じ資料によると、成人の糖尿病患者の4人に3人以上が低中所得国に住んでおり、2022年に670万人が糖尿病が原因で死亡しています。糖尿病の有病率の増加は、インスリンペンによるインスリン投与の需要と意識を高めます。したがって、インスリンペン市場は予測期間に拡大が見込まれます。

World Obesityによると、2025年までに世界全体で27億人の成人が過体重となり、10億人以上が肥満の影響を受け、1億7,700万人の成人が肥満の深刻な影響を受けると推定されています。肥満は糖尿病の主な危険因子の1つです。肥満は脂肪細胞から炎症を引き起こす化学物質を放出させ、インスリンに対する感受性を低下させます。脂肪細胞は、糖尿病の主な原因の1つであるインスリンに反応する細胞の機能とその能力を破壊します。肥満の有病率が増加していることから、糖尿病の有病率が増加し、市場におけるインスリンペンの需要が増加する可能性があります。

Australian Bureau of Statisticの2020年～2022年のレポートによると、糖尿病の割合は55～64歳の10.3％から65～74歳の14.9％へと年齢とともに増加し、オーストラリアでは75歳以上のほぼ5人に1人が糖尿病を患っています。さらに、WHOの2022年の発表によると、2030年までに世界の6人に1人が60歳以上になります。60歳以上の人口に占める割合は、2020年の10億人から世界全体で14億人に増加します。2050年までに、世界の60歳以上の人口は2倍になります。80歳以上の人口は2020年～2050年に3倍に増え、4億2,600万人に達すると予測されています。このように、老年人口の増加は、年齢が糖尿病の主な危険因子の1つであることから、糖尿病患者の有病率に影響を与えます。糖尿病の有病率の増加は、予測期間のインスリンペン市場を強化する見込みです。

さらに、2022年4月、WHOは、糖尿病の予防とケアの持続的な改善を目指す世界的な取り組みである「Global Diabetes Compact」を立ち上げ、特に中低所得国への支援を重視しています。2022年5月には、World Health Assemblyも糖尿病の予防と管理の強化に関する決議に合意しました。WHOは、糖尿病の予防、治療、コントロールに関する意識づくりに継続的に取り組んでいます。このことは、市場におけるインスリンペンの需要を何らかの形で増加させると見込まれます。

当レポートでは、世界のインスリンペン市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 インスリンペン市場レポートのイントロダクション

第2章 インスリンペン市場のエグゼクティブサマリー

• 調査範囲
• 市場の概要
• 競合の評価

第3章 規制分析

• 米国
• 欧州
• 日本
• 中国

第4章 インスリンペン市場の主な要因の分析

• インスリンペン市場の促進要因
  • 糖尿病の有病率の増加
  • 糖尿病になりやすい老年人口の増加
  • デバイスを使用した治療の自己管理に対する意識の向上
  • 遠隔医療の進歩
• インスリンペン市場の抑制要因と課題
  • 遠隔地におけるデバイスの低い入手性
  • 厳格な規制プロセス
• インスリンペン市場の機会
  • クラウドベースシステムの開発と使用
  • 痛くないスマートペンの開発

第5章 インスリンペン市場のポーターのファイブフォース分析

第6章 インスリンペン市場に対するCOVID-19の影響分析

第7章 インスリンペンの市場レイアウト

• 製品タイプ別
  • 再使用可能なインスリンペン
  • 使い捨てインスリンペン
• 技術タイプ別
  • スマートインスリンペン
  • 従来式インスリンペン
• エンドユーザー別
  • 病院、小売薬局
  • 診療所
  • eコマース
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 インスリンペン市場：世界の企業シェア分析 - 主要3～5社

第9章 インスリンペン市場の企業と製品のプロファイル

• Novo Nordisk A/S
• Owen Mumford Ltd.
• Merck Sharp & Dohme Corp.
• Insulet Corporation.
• Biocon Ltd.
• B. Braun Melsungen AG
• Eli Lilly and Co.
• DIABETIC PROMOTIONS.
• Sanofi
• Ypsomed
• Medtronic.
• BERLIN-CHEMIE AG
• pendiq.
• Emperra GmbH E-Health Technologies
• Digital Medics Pty Ltd.
• delfu-medical
• Diamesco Co. Ltd.
• Becton, Dickinson and Company.
• Vansea Medical
• Montmed

第10章 KOLの見解

第11章 プロジェクトのアプローチ

第12章 DelveInsightについて

第13章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis
• Table 3: Insulin pens Market in Global (2021-2030)
• Table 4: Insulin pens Market in Global by Product Type (2021-2030)
• Table 5: Insulin pens Market in Global by Technology Type (2021-2030)
• Table 6: Insulin pens Market in Global by End User (2021-2030)
• Table 7: Insulin pens Market in Global by Geography (2021-2030)
• Table 8: Insulin pens Market in North America (2021-2030)
• Table 9: Insulin pens Market in North America by Country (2021-2030)
• Table 10: Insulin pens Market in the US (2021-2030)
• Table 11: Insulin pens Market in Canada (2021-2030)
• Table 12: Insulin pens Market in Mexico (2021-2030)
• Table 13: Insulin pens Market in Europe (2021-2030)
• Table 14: Insulin pens Market in Europe by Country (2021-2030)
• Table 15: Insulin pens Market in France (2021-2030)
• Table 16: Insulin pens Market in Germany (2021-2030)
• Table 17: Insulin pens Market in the United Kingdom (2021-2030)
• Table 18: Insulin pens Market in Italy (2021-2030)
• Table 19: Insulin pens Market in Spain (2021-2030)
• Table 20: Insulin pens Market in Russia (2021-2030)
• Table 21: Insulin pens Market in Rest of Europe (2021-2030)
• Table 22: Insulin pens Market in APAC (2021-2030)
• Table 23: Insulin pens Market in APAC by Country (2021-2030)
• Table 24: Insulin pens Market in China (2021-2030)
• Table 25: Insulin pens Market in Japan (2021-2030)
• Table 26: Insulin pens Market in India (2021-2030)
• Table 27: Insulin pens Market in Australia (2021-2030)
• Table 28: Insulin pens Market in South Korea (2021-2030)
• Table 29: Insulin pens Market in Rest of APAC (2021-2030)
• Table 30: Insulin pens Market in Rest of World (2021-2030)
• Table 31: Insulin pens Market in RoW by Region (2021-2030)
• Table 32: Insulin pens Market in Middle East (2021-2030)
• Table 33: Insulin pens Market in Africa (2021-2030)
• Table 34: Insulin pens Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis
• Figure 3: Insulin pens Market in Global (2021-2030)
• Figure 4: Insulin pens Market in Global by Product Type (2021-2030)
• Figure 5: Insulin pens Market in Global by Technology Type (2021-2030)
• Figure 6: Insulin pens Market in Global by End User (2021-2030)
• Figure 7: Insulin pens Market in Global by Geography (2021-2030)
• Figure 8: Insulin pens Market in North America (2021-2030)
• Figure 9: Insulin pens Market in North America by Country (2021-2030)
• Figure 10: Insulin pens Market in the US (2021-2030)
• Figure 11: Insulin pens Market in Canada (2021-2030)
• Figure 12: Insulin pens Market in Mexico (2021-2030)
• Figure 13: Insulin pens Market in Europe (2021-2030)
• Figure 14: Insulin pens Market in Europe by Country (2021-2030)
• Figure 15: Insulin pens Market in France (2021-2030)
• Figure 16: Insulin pens Market in Germany (2021-2030)
• Figure 17: Insulin pens Market in the United Kingdom (2021-2030)
• Figure 18: Insulin pens Market in Italy (2021-2030)
• Figure 19: Insulin pens Market in Spain (2021-2030)
• Figure 20: Insulin pens Market in Russia (2021-2030)
• Figure 21: Insulin pens Market in Rest of Europe (2021-2030)
• Figure 22: Insulin pens Market in APAC (2021-2030)
• Figure 23: Insulin pens Market in APAC by Country (2021-2030)
• Figure 24: Insulin pens Market in China (2021-2030)
• Figure 25: Insulin pens Market in Japan (2021-2030)
• Figure 26: Insulin pens Market in India (2021-2030)
• Figure 27: Insulin pens Market in Australia (2021-2030)
• Figure 28: Insulin pens Market in South Korea (2021-2030)
• Figure 29: Insulin pens Market in Rest of APAC (2021-2030)
• Figure 30: Insulin pens Market in Rest of World (2021-2030)
• Figure 31: Insulin pens Market in RoW by Region (2021-2030)
• Figure 32: Insulin pens Market in Middle East (2021-2030)
• Figure 33: Insulin pens Market in Africa (2021-2030)
• Figure 34: Insulin pens Market in South America (2021-2030)
• Figure 35: Market Drivers
• Figure 36: Market Barriers
• Figure 37: Marker Opportunities
• Figure 38: PORTER'S Five Force Analysis

Insulin Pens Market By Product Type (Reusable Insulin Pens And Disposable Insulin Pens), By Technology Type (Smart Insulin Pens And Conventional Insulin Pens), By End User (Hospital And Retail Pharmacy, Clinics, And E-Commerece), by geography is expected to grow at a steady CAGR forecast till 2030 owing to increased prevalence of diabetes mellitus due to genetic factors, obesity, age, and unhealthy lifestyles and enchanced awarness of self-management of diabetes treatment using the device

Global insulin pens market will grow at a CAGR of 3.45% during the forecast period from 2024 to 2030. The increase in demand for insulin pens is primarily attributed to the increase prevalence of diabetes mellitus due to genetic factor, age, obesity, and unhealthy lifestyles, increasing number of geriatric patients, enhanced awareness of self-management through insulin pens and advancements in telemedicine across the world are anticipated to bolster the market, thereby contributing to the growth of the insulin pens market during the forecast period from 2024-2030.

Insulin Pens Market Dynamics:

The insulin pens market is witnessing a growth in product demand owing to various reasons. The increased prevalence of diabetes mellitus worldwide due to various factors such as, genetic, age, obesity, and unhealthy lifestyles increasing number of geriatric patients, and various government initiations across the world are anticipated to bolster the market.

According to World Health Organization (WHO) 2022, in 2019, diabetes was the ninth leading cause of death with an estimated 1.5 million deaths globally, directly caused by diabetes. Diabetes prevalence and mortality has been rising more rapidly in low- and middle-income countries than in high-income countries. WHO also concluded that diabetes is a major cause of blindness, kidney failure, heart attacks, and stroke.

Furthermore, according to International Diabetes Federation, Diabetes Atlas 10th edition report 2022, globally 537 million adults (20-79 years) are living with diabetes. This number is predicted to rise to 643 million by 2030 and 783 million by 2045. As per same source, over three in four adults with diabetes live in low- and middle-income countries and also diabetes was responsible for 6.7 million deaths in 2022. The increasing prevalence of diabetes will increase the demand and awareness of insulin administration by insulin pens. Thus, the market of insulin pens will amplify in the forecast period.

According to World Obesity, it is estimated that 2.7 billion adults will be overweight, over 1 billion affected by obesity, and 177 million adults severely affected by obesity by 2025 globally. Obesity is one the major risk factor for diabetes. Obesity causes fat cells to release pro-inflammatory chemicals, which can make the body less sensitive to the insulin. Fat cells disrupt the function of insulin responsive cells and their ability to respond to insulin, one of the major cause of diabetes. As the prevalence of obesity is increasing and this may increase the prevalence of diabetes owing to increase in demand of insulin pen in the market.

According to Australian Bureau of Statistic 2020-2022 report, the rate of diabetes increased with age from 10.3% for people aged 55-64 years to 14.9% for people aged 65-74 years and almost one in five people over 75 years had diabetes in Australia. Moreover, according to WHO 2022, by 2030, one in six people in the world will be aged 60 years or over. The share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion globally. By 2050, the world's population of people aged 60 years and older will double (2.1 billion). The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million. Thus, the number of geriatric population is increasing which will in turn will affect the prevalence of diabetic patients as age is one of the major risk factor for diabetes mellitus. The increased prevalence of diabetes mellitus will bolster the market of insulin pens in the forecast period.

Furthermore, in April 2022, WHO launched the Global Diabetes Compact, a global initiative aiming for sustained improvements in diabetes prevention and care, with a particular focus on supporting low- and middle-income countries. In May 2022, the World Health Assembly also agreed on a resolution on strengthening prevention and control of diabetes. WHO is continuously working on creating awareness about prevention, treatment and control of diabetes. This will somehow increase the demand of insulin pens in the market.

Moreover, the product launches in local market, in turn, drive the product demand in the market. For instance, in May 2022, Medtronic Plc. announced that it received CE mark for its InPen smart insulin pen for multiple daily injections and its Guardian 4 sensor for better management of diabetes. InPen smart insulin pen is the first-ever smart insulin pen to receive approval in Europe.

Thus, due to the increasing prevalence of diabetes mellitus globally and product launches, will pay way to a rising demand for insulin pen, in turn increasing the insulin pens market growth.

However, lack of accessibility of device in remote regions and stringent regulatory process may pose as a challenge to the insulin pens market growth.

The ongoing COVID-19 pandemic has moderately impacted the market for insulin pens as diabetic patient are at greater risk of getting infection by the virus. As, diabetes was one of the key factor which decreases the recovery rate of a patient suffering from the COVID-19. Therefore, there was an increased demand of insulin pens. In the initial stages of lockdown and due to stringent rules supply of the devices was halted for some time. But, with return of normalcy and masses being vaccinated, the market again picked up the momentum. On the other hand, with the development of telemedicine and e-commerce, pandemic has enhanced the demand of insulin pens due to online sales. Many users preferred home delivery of the products like insulin pens and other diabetes care products to avoid exposure to the virus. Thus, creating a positive impact in the market.

Insulin Pens Market Segment Analysis:

Insulin Pens Market by Product Type (Reusable Insulin Pens and Disposable Insulin Pens), by Technology Type (Smart Insulin Pens and Conventional Insulin Pens), by End-User (Hospital and Retail Pharmacy, Clinics, and E-Commerce), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the Product Type segment of the insulin pens market, the reusable insulin pens are estimated to hold a significant share in the insulin pens market during the forecast period (2024-2030). This can be ascribed to the various advantages that are associated with these devices.

The most important benefit of reusable insulin pen is durability of pen that aids in removing a barrier of large storage space required for disposable insulin pens, and flexibility in carrying a three to five day supply. Furthermore, the reusable insulin pens are also more accurate in terms of fulfilling the dose accuracy as compared with disposable insulin pens.

The demand for reusable insulin pens is expected to increase during the forecasted period. This is owing to the rising technological advancements of reusable insulin pens. For instance, the reusable insulin pens are equipped with additional features such as audible, visual and tactile feedback during dose dialing to support easy application and may reduce the chances of human errors during handling. The reusable pens are now connected through various software's with the smartphone. This helps in tracking the dose-administration in the patient. The software are also connected with healthcare professionals, helping them to track the insulin level and dose-regimen of the patient. Such devices have a sensor and memory that connects with an app to display injection timing and doses. The device sends real-time data via Bluetooth to an application (app) available in smartphones. The application can be assessed by the patient as well as by the physician. The app displays information such as whether the pen is exposed to temperature extremes and other information like most recent blood glucose levels of a patient and anticipated meals, and a dose calculator in the application will recommend the correct amount of insulin to inject. All these features help physician to keep a check on insulin level and dose-regimen of a patient.

Moreover, in various settings reusable pens may be cost-effective as compared to vials and syringes used in disposable insulin pens or in syringes.

Further, these reusable insulin delivery pens are environmentally friendly that could provide ecological advantage in terms of contributing to less plastic waste, compared to disposable pens.

Other factors like comfort in using the device and ease of transport may also contribute as a factor for higher demand of product in the market. For patients requiring long-term insulin therapy, reusable insulin pens may be preferred as disposable insulin pen can cost more in this case.

Moreover, the product launches, in turn, drive the product demand in the market. For instance, in November 2020, Medtronic announced the launch of InPen. It is a reusable pen and integrated with real-time Guardian Connect CGM data. InPen is the first and only FDA-cleared smart insulin pen on the market for people on multiple daily injections (MDI).

Thus, owing to the technological advancements in the area of reusable insulin pens and wide advantages of the device, there will be an increase in the demand for reusable insulin pen, which in turn will drive the insulin pens market growth.

North America is expected to dominate the overall Insulin Pens Market:

Among all the regions, North America is expected to account for the significant share in the global insulin pens market. Growing incidence of diabetic patient due to high consumption of processed food and lifestyle changes, growing incidence of obesity, and technological advancements in medical device like connecting with physician and other features such as audible, visual and tactile feedback will increase the demand for insulin pens in North America, leading to a rise in the overall insulin pens market growth.

For instance, as per the International Diabetes Federation (IDF), Diabetes Atlas Tenth edition 2022, in 2022, approximately 51 million adults (20-79 years) were living with diabetes in North America and the total number of people living with diabetes is projected to rise to 7 million by 2030 and 63 million by 2045. As per the same source, it is estimated that almost 1 in 4 (240 million) adults living in North America with diabetes are undiagnosed. Moreover, as per the IDF, Diabetes Atlas Tenth edition 2022, in 2022, more than 1.2 million children and adolescents (0-19 years) were living with type 1 diabetes and one in six live births (21 million) were affected by diabetes during pregnancy. As per above statistics, it can be concluded that the prevalence of diabetes mellitus in North America is increasing, it will increase the use of insulin pen among the patient thereby increasing the product demand in the market.

According to National Institute of Diabetes and Digestive and Kidney Disease (NIH), National Diabetes Statistics Report, 2020, an estimated 88 million adults' ages 18 years or older were having prediabetes in United States. Prediabetes is a condition in which blood glucose levels are higher than normal but not high enough for a diagnosis of diabetes. Moreover, as per the same source, in US more men (37.4% of U.S. adults) than women (29.2%) had prediabetes and among adolescents ages 12 to 18 years, more than 1 in 6 (18% of U.S. adolescents) had prediabetes. The rate of prevalence of prediabetes and diabetes is expected to increase in United States in the forecast period owing to the increase in the demand of insulin pen.

Furthermore, unhealthy life is contributing for increase in the prevalence of chronic disease like diabetes. Adults who eat a healthy diet live longer, have a lower risk of obesity, heart disease, type 2 diabetes, and certain cancers. Most Americans, however, do not follow a healthy lifestyle. As per Centers for Disease Control and Prevention (CDC), 2022, fewer than 1 in 10 adults and adolescents eat enough fruits and vegetables, and 9 in 10 Americans aged 20 years or older consume more than the recommended amount of sodium. Moreover, only one in four is exclusively breastfed through six months of age, leading to weak immune system. CDC also concluded the relation between unhealthy lifestyle and obesity.

Moreover, according to CDC, in the United States, 19% of young people aged 2 to 19 years and 40% of adults have obesity, which can put them at risk for heart disease, type 2 diabetes, and some cancers furthermore, more than one in three people have prediabetes, and more than 8 in 10 of them don't know they have prediabetes. From the above data it can be concluded that unhealthy lifestyle and obesity is one of the major cause for causing diabetes. This will increase the prevalence of diabetes in the forecast period owing to increase the demand of insulin pens in the North America market.

Another factor responsible for increasing the product demand is technological advancements in the medical device. Various features like dose range control, smartphone maintenance and updating, and development of cloud-based software are increasing the demand of the insulin pen in the North America. All the features are making the pens more and more convent and easy to use, thereby bolstering the market.

Thus, all the above-mentioned factors are anticipated to propel the market for insulin pens in the North America.

Insulin Pens Market Key Players:

Some of the key market players operating in the insulin pens market include Novo Nordisk A/S, Owen Mumford Ltd, Sanofi Diabetes, Merck Sharp & Dohme Corp., Insulet Corporation., Biocon Ltd., B. Braun Melsungen AG, Eli Lilly and Co., DIABETIC PROMOTIONS., Ypsomed Logo, Medtronic., BERLIN-CHEMIE AG, pendiq., Emperra GmbH E-Health Technologies, Digital Medics Pty Ltd., delfu-medical, Diamesco Co. Ltd. e, Becton, Dickinson and Company., Vansea Medical, Montmedand, others., among others.

Recent Developmental Activities in the Insulin Pens Market:

In June 2022, Novo Nordisk Pharma announced that it has obtained Japanese regulatory approval for NovoPen 6 and NovoPen Echo Plus as medical devices, the first smart insulin pens to be approved in the country.

In May 2022, Eli Lilly and Company announced that it has signed strategic international agreements with four companies - DexCom, Inc., Glooko Inc., myDiabby Healthcare and Roche - to advance connected solutions and streamline care for people living with diabetes in markets outside of the United States.

In August 2020, Medtronic announced the acquisition of Companion Medical, manufacturer of InPen.

Key Takeaways from the Insulin Pens Market Report Study

• Market size analysis for current insulin pens market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the insulin pens market.
• Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
• Key companies dominating the global insulin pens market.
• Various opportunities available for the other competitor in the insulin pens market space.
• What are the top performing segments in 2023? How these segments will perform in 2030.
• Which is the top-performing regions and countries in the current insulin pens market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for insulin pens market growth in the coming future?

Target Audience who can be benefited from this Insulin Pens Market Report Study

• Insulin pens products providers
• Research organizations and consulting companies
• Insulin pens-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in insulin pens
• Various End-users who want to know more about the insulin pens market and latest technological developments in the insulin pens market.

Frequently Asked Questions for Insulin Pens Market:

1. What are insulin pens?

An insulin pens, is a medical device which inject the insulin into the subcutaneous tissue. Insulin is a vital hormone for people who have diabetes. Insulin pens contain a cartridge, a dial to measure dosage, and a disposable needle.

2. What is the market for Global insulin pens?

Global insulin pens market will grow at a CAGR of 3.45% during the forecast period from 2024 to 2030.

3. What are the drivers for the Global insulin pens market?

The insulin pens market is witnessing a positive market growth owing to increased prevalence of diabetes mellitus, increasing number of geriatric patients, enhanced awareness of self-management through insulin pens and advancements in telemedicine across the world are anticipated to bolster the market.

4. Who are the key players operating in the Global insulin pens market?

Some of the key market players operating in the insulin pens market include Novo Nordisk A/S, Owen Mumford Ltd, Sanofi Diabetes, Merck Sharp & Dohme Corp., Insulet Corporation., Biocon Ltd., B. Braun Melsungen AG, Eli Lilly and Co., DIABETIC PROMOTIONS., Ypsomed Logo, Medtronic., BERLIN-CHEMIE AG, pendiq., Emperra GmbH E-Health Technologies, Digital Medics Pty Ltd., delfu-medical, Diamesco Co. Ltd. e, Becton, Dickinson and Company., Vansea Medical, Montmedand, others.

5. Which region has the highest share in insulin pens market?

North America is expected to hold the highest share in the revenue in the Insulin pens market during the forecast period. Growing incidence of diabetic patient due to high consumption of processed food and lifestyle changes, growing incidence of obesity, and technological advancements in medical device like connecting with physician through application and other features will increase the demand for insulin pens in North America, leading to a rise in the overall insulin pens market growth in this region.

Table of Contents

1.Insulin pens Market Report Introduction

2.Insulin pens Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

• 3.1. The United States
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Insulin pens Market Key Factors Analysis

• 4.1. Insulin pens Market Drivers
  • 4.1.1. Increase prevalence of diabetes mellitus
  • 4.1.2. Increasing number of geriatric population prone to diabetes
  • 4.1.3. Enhanced awareness of self-management of treatment using the device
  • 4.1.4. Advancements in telemedicine
• 4.2. Insulin pens Market Restraints and Challenges
  • 4.2.1. Lack of accessibility of device in remote regions
  • 4.2.2. Stringent regulatory process
• 4.3. Insulin pens Market Opportunities
  • 4.3.1. Development and use of cloud-based system
  • 4.3.2. Development of pain-less smart pens

5. Insulin pens Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Insulin pens Market

7. Insulin pens Market Layout

• 7.1. By Product Type
  • 7.1.1. Reusable Insulin Pens
  • 7.1.2. Disposable Insulin Pens
• 7.2. By Technology Type
  • 7.2.1. Smart Insulin Pens
  • 7.2.2. Conventional Insulin Pens
• 7.3. By End User
  • 7.3.1. Hospital and Retail Pharmacy
  • 7.3.2. Clinics
  • 7.3.3. E-commerce
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States
    • 7.4.1.2. Canada
    • 7.4.1.3. Mexico
  • 7.4.2. Europe
    • 7.4.2.1. France
    • 7.4.2.2. Germany
    • 7.4.2.3. United Kingdom
    • 7.4.2.4. Italy
    • 7.4.2.5. Spain
    • 7.4.2.6. Russia
    • 7.4.2.7. Rest of Europe
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China
    • 7.4.3.2. Japan
    • 7.4.3.3. India
    • 7.4.3.4. Australia
    • 7.4.3.5. South Korea
    • 7.4.3.6. Rest of Asia Pacific
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East
    • 7.4.4.2. Africa
    • 7.4.4.3. South America

8. Insulin pens Market Global Company Share Analysis - Key 3-5 Companies

9. Insulin pens Market Company and Product Profiles

• 9.1. Novo Nordisk A/S
  • 9.1.1. Company Overview
  • 9.1.2. Company Snapshot
  • 9.1.3. Financial Overview
  • 9.1.4. Product Listing
  • 9.1.5. Entropy
• 9.2. Owen Mumford Ltd.
  • 9.2.1. Company Overview
  • 9.2.2. Company Snapshot
  • 9.2.3. Financial Overview
  • 9.2.4. Product Listing
  • 9.2.5. Entropy
• 9.3. Merck Sharp & Dohme Corp.
  • 9.3.1. Company Overview
  • 9.3.2. Company Snapshot
  • 9.3.3. Financial Overview
  • 9.3.4. Product Listing
  • 9.3.5. Entropy
• 9.4. Insulet Corporation.
  • 9.4.1. Company Overview
  • 9.4.2. Company Snapshot
  • 9.4.3. Financial Overview
  • 9.4.4. Product Listing
  • 9.4.5. Entropy
• 9.5. Biocon Ltd.
  • 9.5.1. Company Overview
  • 9.5.2. Company Snapshot
  • 9.5.3. Financial Overview
  • 9.5.4. Product Listing
  • 9.5.5. Entropy
• 9.6. B. Braun Melsungen AG
  • 9.6.1. Company Overview
  • 9.6.2. Company Snapshot
  • 9.6.3. Financial Overview
  • 9.6.4. Product Listing
  • 9.6.5. Entropy
• 9.7. Eli Lilly and Co.
  • 9.7.1. Company Overview
  • 9.7.2. Company Snapshot
  • 9.7.3. Financial Overview
  • 9.7.4. Product Listing
  • 9.7.5. Entropy
• 9.8. DIABETIC PROMOTIONS.
  • 9.8.1. Company Overview
  • 9.8.2. Company Snapshot
  • 9.8.3. Financial Overview
  • 9.8.4. Product Listing
  • 9.8.5. Entropy
• 9.9. Sanofi
  • 9.9.1. Company Overview
  • 9.9.2. Company Snapshot
  • 9.9.3. Financial Overview
  • 9.9.4. Product Listing
  • 9.9.5. Entropy
• 9.10. Ypsomed
  • 9.10.1. Company Overview
  • 9.10.2. Company Snapshot
  • 9.10.3. Financial Overview
  • 9.10.4. Product Listing
  • 9.10.5. Entropy
• 9.11. Medtronic.
  • 9.11.1. Company Overview
  • 9.11.2. Company Snapshot
  • 9.11.3. Financial Overview
  • 9.11.4. Product Listing
  • 9.11.5. Entropy
• 9.12. BERLIN-CHEMIE AG
  • 9.12.1. Company Overview
  • 9.12.2. Company Snapshot
  • 9.12.3. Financial Overview
  • 9.12.4. Product Listing
  • 9.12.5. Entropy
• 9.13. pendiq.
  • 9.13.1. Company Overview
  • 9.13.2. Company Snapshot
  • 9.13.3. Financial Overview
  • 9.13.4. Product Listing
  • 9.13.5. Entropy
• 9.14. Emperra GmbH E-Health Technologies
  • 9.14.1. Company Overview
  • 9.14.2. Company Snapshot
  • 9.14.3. Financial Overview
  • 9.14.4. Product Listing
  • 9.14.5. Entropy
• 9.15. Digital Medics Pty Ltd.
  • 9.15.1. Company Overview
  • 9.15.2. Company Snapshot
  • 9.15.3. Financial Overview
  • 9.15.4. Product Listing
  • 9.15.5. Entropy
• 9.16. delfu-medical
  • 9.16.1. Company Overview
  • 9.16.2. Company Snapshot
  • 9.16.3. Financial Overview
  • 9.16.4. Product Listing
  • 9.16.5. Entropy
• 9.17. Diamesco Co. Ltd.
  • 9.17.1. Company Overview
  • 9.17.2. Company Snapshot
  • 9.17.3. Financial Overview
  • 9.17.4. Product Listing
  • 9.17.5. Entropy
• 9.18. Becton, Dickinson and Company.
  • 9.18.1. Company Overview
  • 9.18.2. Company Snapshot
  • 9.18.3. Financial Overview
  • 9.18.4. Product Listing
  • 9.18.5. Entropy
• 9.19. Vansea Medical
  • 9.19.1. Company Overview
  • 9.19.2. Company Snapshot
  • 9.19.3. Financial Overview
  • 9.19.4. Product Listing
  • 9.19.5. Entropy
• 9.20. Montmed
  • 9.20.1. Company Overview
  • 9.20.2. Company Snapshot
  • 9.20.3. Financial Overview
  • 9.20.4. Product Listing
  • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us